Inventiva annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris

Inventiva announced on June 2, 2026, that trading of its ordinary shares on Euronext Paris will be temporarily suspended starting at market open (9:00 CEST) pending disclosure of a financing operation. Trading is expected to resume later that day around 15:30 CEST, coinciding with potential trading resumption on Nasdaq. The company is a clinical-stage biopharmaceutical firm developing lanifibranor, a pan-PPAR agonist, for treating MASH (metabolic dysfunction-associated steatohepatitis).

06/02/2026, 1:30 AM • GlobeNewswire

Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris

Inventiva, a clinical-stage biopharmaceutical company developing oral therapies for MASH treatment, announced a temporary trading halt on Euronext Paris on June 2, 2026, ahead of a proposed financing transaction. Trading was expected to resume at approximately 3:30 p.m. CEST, coinciding with the opening of Nasdaq trading. The company reported Q1 2026 cash and equivalents of €75.0 million plus €121.5 million in short-term deposits.

06/02/2026, 1:30 AM • GlobeNewswire

Inventiva Reports 2026 First Quarter Financial Information¹

Inventiva, a clinical-stage biopharmaceutical company, reported Q1 2026 financial results showing cash and cash equivalents of €75.0 million and short-term deposits of €121.5 million, down from €99.3 million and €131.6 million respectively at year-end 2025. The company estimates its current resources will fund operations until mid-Q1 2027, or mid-Q3 2027 if Tranche 3 warrants from its October 2024 structured financing are fully exercised for €116.0 million. The company generated no revenues in Q1 2026 and expects NATiV3 Phase 3 trial topline results in Q4 2026.

05/26/2026, 4:00 PM • GlobeNewswire

Inventiva publie ses informations financières du premier trimestre 2026¹

Inventiva, a clinical-stage biopharmaceutical company, reported cash and equivalents of €75 million and short-term deposits of €121.5 million as of March 31, 2026. The company estimates its liquidity will fund operations until mid-Q1 2027, or potentially mid-Q3 2027 if warrant exercises from its structured financing reach €116 million. No revenue was recorded in Q1 2026. Key milestone: NATiV3 Phase 3 trial results for lanifibranor (MASH treatment) are expected in Q4 2026.

05/26/2026, 4:00 PM • GlobeNewswire

Inventiva to Present at 2026 Jefferies Global Healthcare Conference

Inventiva, a clinical-stage biopharmaceutical company developing oral therapies for MASH treatment, announced that CEO Andrew Obenshain will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, in New York City. The company is evaluating lanifibranor, a pan-PPAR agonist, in the NATiV3 Phase 3 clinical trial.

05/21/2026, 4:00 PM • GlobeNewswire

Inventiva présentera lors de la 2026 Jefferies Global Healthcare Conference

Inventiva announced that CEO Andrew Obenshain will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026 in New York. The biopharmaceutical company is developing lanifibranor, an oral therapy for MASH treatment, currently in Phase 3 clinical trials.

05/21/2026, 4:00 PM • GlobeNewswire

Inventiva présentera plusieurs abstracts lors de l’EASL Congress 2026

Inventiva announced it will present two abstracts at the EASL Congress 2026 in Barcelona (May 27-30) showcasing lanifibranor's improvements in histological parameters and cardiometabolic markers in MASH patients, independent of weight change and associated with adiponectin induction. The company will also exhibit at booth 35.

05/13/2026, 2:30 AM • GlobeNewswire

Inventiva to Present Abstracts at the EASL Congress 2026

Inventiva announced it will present two abstracts at the EASL Congress 2026 in Barcelona (May 27-30) showcasing lanifibranor's effectiveness in treating metabolic dysfunction-associated steatohepatitis (MASH). The presentations highlight improvements in histological parameters, cardiometabolic markers, and liver sinusoidal endothelial cell changes independent of weight loss. Lanifibranor is a pan-PPAR agonist currently in Phase 3 clinical trials and has received FDA Breakthrough Therapy and Fast Track designations.

05/13/2026, 2:30 AM • GlobeNewswire

Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor

Inventiva announced the recruitment of three new senior executives: Axel-Sven Malkomes as Chief Financial Officer, Susan Coles as Chief Legal Officer, and Pamela Herbster as Chief People Officer. These appointments strengthen the company's leadership team ahead of the anticipated Phase 3 top-line data readout for lanifibranor in Q4 2026. Previous CFO Jean Volatier will transition to EVP Finance & Corporate Social Responsibility.

04/22/2026, 4:00 PM • GlobeNewswire

Inventiva renforce son équipe de direction à l’approche des résultats de Phase 3 du lanifibranor

Inventiva announced the appointment of three new executives: Axel-Sven Malkomes as Chief Financial Officer, Susan Coles as General Counsel, and Pamela Herbster as Chief Human Resources Officer. These hires strengthen the company's leadership ahead of expected Phase 3 trial results for lanifibranor in Q4 2026. Previous executives Jean Volatier and Nathalie Harroy transition to new roles within the company.

04/22/2026, 4:00 PM • GlobeNewswire

Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2025 et de son Rapport Annuel 2025 (« Form 20-F »)

Inventiva, a clinical-stage biopharmaceutical company, has filed its 2025 Universal Registration Document with the AMF and its Form 20-F with the SEC. The company reported €4.5 million in revenues for 2025 and held €99.3 million in cash and €131.6 million in short-term deposits as of December 31, 2025. Inventiva is developing lanifibranor, a pan-PPAR agonist, for the treatment of MASH (metabolic dysfunction-associated steatohepatitis) in its Phase 3 NATiV3 clinical trial.

04/08/2026, 4:00 PM • GlobeNewswire

Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F

Inventiva, a clinical-stage biopharmaceutical company, announced the filing of its 2025 Universal Registration Document with the French AMF and its 2025 Annual Report on Form 20-F with the SEC. The company reported 2025 revenues of €4.5 million and cash/short-term deposits totaling €230.9 million as of December 31, 2025. Inventiva continues to evaluate lanifibranor, a pan-PPAR agonist, in the NATiV3 Phase 3 clinical trial for MASH treatment.

04/08/2026, 4:00 PM • GlobeNewswire

Inventiva annonce la publication et la présentation de ses résultats financiers annuels 2025

Inventiva, a biopharmaceutical company developing oral therapies for MASH treatment, announced it will publish its 2025 annual financial results on March 30, 2026, followed by an earnings conference call on March 31, 2026. The company is currently evaluating lanifibranor, a pan-PPAR agonist, in a Phase 3 clinical trial for treating adult patients with metabolic dysfunction-associated steatohepatitis.

03/23/2026, 5:00 PM • GlobeNewswire

Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results

Inventiva, a clinical-stage biopharmaceutical company developing oral therapies for MASH treatment, announced it will release its 2025 full-year financial results on March 30, 2026, followed by a management conference call on March 31, 2026. The company is currently evaluating lanifibranor, a pan-PPAR agonist, in the NATiV3 Phase 3 clinical trial.

03/23/2026, 5:00 PM • GlobeNewswire

Inventiva reports preliminary 2025¹ fiscal year financial results

Inventiva, a clinical-stage biopharmaceutical company, reported preliminary 2025 financial results showing cash and cash equivalents of €99.3 million plus €131.6 million in short-term deposits. The company generated €4.5 million in revenues and used €104.6 million in operating activities. Following a U.S. public offering raising $172.5 million and structured financing, Inventiva estimates cash runway until mid-Q1 2027, or mid-Q3 2027 if Tranche 3 warrants are fully exercised. R&D expenses focused on lanifibranor development for MASH treatment amounted to €86.9 million.

02/17/2026, 2:30 AM • GlobeNewswire